---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-005886"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:22:15.270768+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q1 revenue up 14% to $6.3M, net loss widens to $9.2M; FY guidance reaffirmed

## Summary
- Q1 2024 revenue $6.3M (+14% YoY) driven by 86% growth in Diagnostics and 9% in Therapeutic Devices.
- Net loss $9.2M ($0.01/share) vs $6.4M loss in Q1 2023; adjusted non-GAAP EBITDA loss $6.2M.
- Gross margin 66%; consumable revenue $4.0M (64% of sales), capital revenue $2.2M (+30% YoY).
- Cash and securities $90.9M at March 31, 2024, down from $100.5M at Dec 31, 2023.
- FY 2024 revenue guidance maintained at $31-35M, up ~39% at high end from $25.2M in 2023.

## SEC filing metadata
- accession: 0001654954-24-005886
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/0001654954-24-005886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-005886
- JSON: https://secwatch.observer/filing/0001654954-24-005886.json
- Plain text: https://secwatch.observer/filing/0001654954-24-005886.txt

## Key facts
- Earnings Releases
  Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.
  - Period: full year 2024
  - Revenue: $31 to $35 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: For the full year 2024, the Company continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 39% at the high end of the range, over full year 2023 revenue of $25.2 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/0001654954-24-005886-index.htm
- Earnings Releases
  Zomedica Corp. reported the quarter ended March 31, 2024 results: revenue $6.3 million, net income $9.2 million, EPS $0.01 per share.
  - Period: the quarter ended March 31, 2024
  - Revenue: $6.3 million
  - Net income: $9.2 million
  - EPS: $0.01 per share
  - Result: reported results
  source text: Revenue for the three months ended March 31, 2024, was $6.3 million, compared to $5.5 million for the three months ended March 31, 2023, an increase of $0.8 million or approximately 14%. The increase was driven by growth in both operating segments: Therapeutic Devices and Diagnostics. Cost of revenue was $2.1 million, compared to $1.6 million for the three months ended March 31, 2023, an increase of $0.5 million. Margins remained strong at 66%, in line with expectations. Adjusting for our Qorvo Biotechnologies LLC (“QBT”) acquisition and other one-time items brings our gross margin for the quarter to over 69%, in line with recent levels. Operating expenses were $14.5 million, compared to $11.3 million for the three months ended March 31, 2023, an increase of $3.2 million or 28%. When adjusted for one-time, non-recurring charges, and expenses associated with ongoing QBT operations, total operating expenses grew just over 20% on a comparative basis. We continue to expect total operating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495424005886/0001654954-24-005886-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.